The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Prolonged clinical benefit with metronomic capecitabine plus oral vinorelbine as treatment of metastatic breast cancer: Results from a phase II study.
Laura Orlando
No relevant relationships to disclose
Palma Fedele
No relevant relationships to disclose
Paola Schiavone
No relevant relationships to disclose
Angelo Nacci
No relevant relationships to disclose
Nicola Calvani
No relevant relationships to disclose
Enrica Mazzoni
No relevant relationships to disclose
Annamaria Quaranta
No relevant relationships to disclose
Margherita Cinefra
No relevant relationships to disclose
Saverio Cinieri
No relevant relationships to disclose